Two studies involving nearly 14,000 patients indicate the blood thinner enoxaparin, a newcomer to the market, is no more effective than heparin in treating victims of heart attacks or chest pain. Aventis' enoxaparin is much more expensive than heparin, but is popular with doctors and patients because it can be delivered by injection rather than a continuous IV drip.

Full Story:
USA Today

Related Summaries